|
|
|
|
|
|
|
|
|
|
Course Criteria
Add courses to your favorites to save, share, and find your best transfer school.
-
1.00 Credits
Students read selected Wall Street Journal health-related articles and discuss the events that have resulted in news coverage each week in the areas of pharmaceutical/biotechnology, providers/insurance, research, policy, and medical products.
-
3.00 Credits
The first course of a two-course sequence that examines and focuses on models and theories of behavior change. Particular focus on primary models of behavior change relative to public health, health education, preventive health, health promotion, and pharmacological practice. From a combination of pharmacological and public health practice, student gains a broad understanding of the various models and theories that may enhance understanding of how health-behavior change models and theories can be applied to assessing a patient's level of behavior change. Students use knowledge to meet the individual needs of the patient.
-
3.00 Credits
Examines the concepts and constructs of health behavior change models and theories presented in RXSA 751: Social and Behavioral Aspects of Pharmacy Practice. Presents students with real-world clinical cases and scenarios, as well as with integrated clinical rotations in the course--providing them opportunities to apply knowledge from their didactic lecture material to practical hands-on clinical cases they may encounter during clinical rotations. Provides students with practical and functional knowledge of health behavior- change models and theories as they are applied to clinical pharmacy practice. Prerequisite: RXSA 751.
-
2.00 Credits
Builds on the principles of biostatistics and drug information to develop the skills necessary for a practitioner to design and develop a clinical research study worthy of scholarly publication and presentation. Highly recommended for students who wish to pursue a career in managed care, pharmacy practice in an academic setting, or as a clinical coordinator in hospital settings. Offered Spring Quarter of PY3. Prerequisite: Completion of RXDI 664 & RXSA 640 with a grade of B- or better.
-
2.00 Credits
Part of a twelve-course sequence taught over two years. Focuses on pathophysiology and management of disease states, pharmacology of the drug classes indicated, and the clinical pharmacokinetics that govern drug administration. Develops an understanding of the basic pharmacologic concepts of therapeutics, receptor theory, drug metabolism, and drug interactions. Covers tools to effectively assess therapy, including interpretation of laboratory values and construction of SOAP notes. Prerequisite: Successful completion of all P1-level courses and P2; AQ standing.
-
2.50 Credits
Part of a twelve-course sequence. Covers the pathophysiology, management, and drug therapy of conditions related to electrolyte and fluid disturbances; as well as dietary requirements and sources of electrolytes. Addresses pathophysiology, management, and drug therapy of anemias. Enables students to manage electrolyte and fluid disorders and anemias, establish and employ rational treatment, and provide parameters to monitor progress of the regimens. Prerequisite: Successful completion of all P1-level courses and P2; AQ standing.
-
3.00 Credits
Part of a twelve-course sequence. Includes pathophysiology, pharmacology, pharmacokinetics, pharmacotherapy, and clinical-trial evidence as related to renal and respiratory diseases. Enables students to integrate their knowledge of these disciplines to manage renal and respiratory diseases by establishing and employing rational treatment and providing parameters to monitor progress of the regimens. Prerequisite: RXTH 670, RXTH 671.
-
3.50 Credits
Part of a twelve-course sequence. Introduces students to the pharmacology, pharmacokinetics, and pharmacodynamics of agents used in the treatment of endocrine and GI dysfunction; as well as management (evaluation, treatment, monitoring, and follow-up) of patients with endocrine and GI dysfunctions. Students integrate knowledge, attitudes, and skills in a variety of ways to accomplish course outcomes. Includes pathophysiology, pharmacology, pharmacokinetics, pharmacotherapy, and clinical-trial evidence as they relate to endocrine and GI drugs. Enables students to integrate their knowledge of the disciplines studied in the context of formulating an individualized pharmacotherapeutic plan for a given patient. Prerequisite: completion of all P1 and AQ P2 courses.
-
3.50 Credits
Part of a twelve-course sequence. Introduces students to the pharmacology, pharmacokinetics, and pharmacodynamics of cardiovascular agents; as well as management (evaluation, treatment, monitoring, and follow-up) of patients with common cardiovascular disorders. Students integrate knowledge, attitudes, and skills in a variety of ways to accomplish course outcomes. Includes anatomy, physiology, pharmacology, pharmacokinetics, pharmacotherapy, and clinical-trial evidence as they relate to cardiology. Enables students to integrate their knowledge of the disciplines studied in the context of formulating an individualized pharmacotherapeutic plan for a given patient. Prerequisite: P2, SQ standing.
-
3.50 Credits
Part of a twelve-course sequence. Introduces students to the pharmacology, pharmacokinetics, and pharmacodynamics of agents used in the treatment of endocrine and GI dysfunction; as well as management (evaluation, treatment, monitoring, and follow-up) of patients with endocrine and GI dysfunctions. Students integrate knowledge, attitudes, and skills in a variety of ways to accomplish course outcomes. Includes pathophysiology, pharmacology, pharmacokinetics, pharmacotherapy, and clinical-trial evidence as they relate to endocrine and GI drugs. Enables students to integrate their knowledge of the disciplines studied in the context of formulating an individualized pharmacotherapeutic plan for a given patient.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Privacy Statement
|
Terms of Use
|
Institutional Membership Information
|
About AcademyOne
Copyright 2006 - 2024 AcademyOne, Inc.
|
|
|